CTOs on the Move

Unybrands

www.unybrands.com

 
We are serial acquirers of e-commerce, Amazon FBA and DTC stores: We work fast, reliably and with integrity. Our expert Buy-and-Build team will be by your side throughout the entire acquisition process.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Unybrands raised $25M on 02/17/2021

Similar Companies

XAHIVE

#Cyber security company offering secure web & mobile app! Compliant with NIST, GDPR, PIPEDA, DMCA & HIPAA. Protect your communication!

Yooz

Yooz provides the smartest, most powerful and easiest-to-use cloud-based Purchase-to-Pay (P2P) automation solution. It delivers unmatched savings, speed and security with affordable zero-risk subscriptions to more than 4,000 customers and 200,000 users worldwide. Yooz`s unique solution leverages Artificial Intelligence and RPA technologies to deliver an amazing level of automation with extreme simplicity, traceability and end-to-end customizable features. It integrates seamlessly with more than 250 financial systems, exceeding any other solution on the market. Yooz is a fast-growing, award-winning, SaaS innovator that is the perfect fit for mid-size organizations across all sectors. It has been recognized as a Great Place to Work®, 10 Best Cloud Solution Provider by Industry Era, Best of SaaS Showplace (BoSS) by THINKstrategies, Top 10 Accounting Solution Provider by CFO Tech Outlook, and Top 50 Company to Watch by Spend Matters. Yooz North America is headquartered in the Dallas, Texas metropolitan area with global offices in Europe.

Interlink Cloud Advisors

Interlink Cloud Advisors is a leading system integrator for Microsofts cloud solutions, helping customers migrate to Office 365, Azure, Intune and other cloud-based services.

Immunome

Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.